MedTrace Logo

SCOT Registry: Small Cell Lung Cancer Treatment and Outcome

NCT00997061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2014-02-03

No results posted yet for this study

Summary

The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC.

Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC.

Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.

Conditions

  • Lung Cancer, Small Cell

Interventions

DRUG

HYCAMTIN

Observing patients on HYCAMTIN and other drugs for SCLC.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Austria
  • Czechia
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Lithuania
  • Netherlands
  • Poland
  • Slovenia
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997061 on ClinicalTrials.gov